Atwater Malick’s AbbVie ABBV Stock Holding History

Atwater Malick’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$658K	Sell	3,027 -210	-6%	-$46.6K	0.18%	51
2025 Q4	$740K	Buy	3,237 +391	+14%	+$89.1K	0.2%	45
2025 Q3	$659K	Hold	2,846	–	–	0.19%	48
2025 Q2	$528K	Buy	2,846 +135	+5%	+$25.1K	0.17%	54
2025 Q1	$568K	Sell	2,711 -13	-0.5%	-$2.53K	0.19%	50
2024 Q4	$484K	Hold	2,724	–	–	0.16%	49
2024 Q3	$538K	Sell	2,724 -40	-1%	-$7.46K	0.17%	51
2024 Q2	$474K	Hold	2,764	–	–	0.16%	53
2024 Q1	$503K	Buy	2,764 +1,095	+66%	+$189K	0.18%	56
2023 Q4	$259K	Sell	1,669 -468	-22%	-$68.2K	0.1%	62
2023 Q3	$319K	Hold	2,137	–	–	0.14%	55
2023 Q2	$288K	Buy	2,137 +510	+31%	+$74.8K	0.12%	59
2023 Q1	$259K	Buy	1,627 +24	+1%	+$3.67K	0.12%	55
2022 Q4	$259K	Buy	+1,603	New	+$246K	0.13%	51
2019 Q4	–	Sell	-686	Closed	-$52K	–	39
2019 Q3	$52K	Buy	+686	New	+$47K	0.04%	74

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Atwater Malick's ABBV Position: Q1 2026 in Review

Atwater Malick reduced its AbbVie (ABBV) stake by 6.5% in Q1 2026, selling an estimated $46.6K and leaving 3,027 shares worth $658K. The position accounts for 0.18% of the portfolio, ranked #51.

Atwater Malick first reported a position in ABBV in Q3 2019 and has held it in 15 quarters since. The position peaked at $740K in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Atwater Malick held 3,027 shares of AbbVie worth $658K as of Q1 2026.
Atwater Malick sold 210 AbbVie shares in Q1 2026, an estimated $46.6K.
AbbVie made up 0.18% of Atwater Malick's portfolio in Q1 2026, its #51 holding.
Atwater Malick first reported a position in AbbVie in Q3 2019 and has held it in 15 quarters since.
Atwater Malick's AbbVie position peaked at $740K in Q4 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Atwater Malick's 13F filing for Q1 2026, filed 22 Apr 2026.